Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
OBJECTIVE
To evaluate potential detrimental effects of exemestane on bone and lipid metabolism.


METHODS
Postmenopausal women with early breast cancer were randomly assigned to exemestane 25 mg daily or placebo for 2 years in a double-blind setting. Primary objective was to evaluate the effect of exemestane on bone mineral density. Secondary objectives were effects on bone biomarkers, plasma lipids, coagulation factors, and homocysteine. Planned size was 128 patients.


RESULTS
One hundred forty-seven patients were enrolled. All patients completed their 24-month visit except for those discontinuing treatment at an earlier stage. The mean annual rate of bone mineral density loss was 2.17% v 1.84% in the lumbar spine (P = .568) and 2.72% v 1.48% in the femoral neck (P = .024) in the exemestane and placebo arm, respectively. The mean change in T-score after 2 years was -0.21 for exemestane and -0.11 on placebo in the hip, and -0.30 and -0.21, respectively, in the lumbar spine. Exemestane significantly increased serum level and urinary excretion of bone resorption, but also bone formation markers. Except for a modest reduction in high-density lipoprotein cholesterol (P < .001) and apolipoprotein A1 (P = .004), exemestane had no major effect on lipid profile, homocysteine levels, or coagulation parameters.


CONCLUSIONS
Exemestane modestly enhanced bone loss from the femoral neck without significant influence on lumbar bone loss. Except for a 6% to 9% drop in plasma high-density lipoprotein cholesterol, no major effects on serum lipids, coagulation factors, or homocysteine were recorded. Bone mineral density should be assessed according to the US Preventive Services Task Force guidelines.
Lønning
Per E
PE
Section of Oncology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway. per.lonning@helse-bergen.no
Geisler
Jürgen
J
Krag
Lars E
LE
Erikstein
Bjørn
B
Bremnes
Yngve
Y
Hagen
Anne I
AI
Schlichting
Ellen
E
Lien
Ernst A
EA
Ofjord
Erik S
ES
Paolini
Jolanda
J
Polli
Anna
A
Massimini
Giorgio
G
D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause
D000730:Androstadienes; D047072:Aromatase Inhibitors; D008055:Lipids; D010919:Placebos; C056516:exemestane